253 related articles for article (PubMed ID: 32003684)
1. Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.
Abbas G; Haq QMI; Hamaed A; Al-Sibani M; Hussain H
Curr Pharm Des; 2020; 26(4):501-508. PubMed ID: 32003684
[TBL] [Abstract][Full Text] [Related]
2. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.
Chepurny OG; Matsoukas MT; Liapakis G; Leech CA; Milliken BT; Doyle RP; Holz GG
J Biol Chem; 2019 Mar; 294(10):3514-3531. PubMed ID: 30622136
[TBL] [Abstract][Full Text] [Related]
3. Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1.
Gastaldelli A; Gaggini M; DeFronzo R
Curr Opin Clin Nutr Metab Care; 2017 Jul; 20(4):300-309. PubMed ID: 28463898
[TBL] [Abstract][Full Text] [Related]
4. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
8. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
10. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
[TBL] [Abstract][Full Text] [Related]
11. The structure and function of the glucagon-like peptide-1 receptor and its ligands.
Donnelly D
Br J Pharmacol; 2012 May; 166(1):27-41. PubMed ID: 21950636
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
13. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
15. Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes.
Lang S; Yang J; Yang K; Gu L; Cui X; Wei T; Liu J; Le Y; Wang H; Wei R; Hong T
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139602
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
17. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
[TBL] [Abstract][Full Text] [Related]
18. Targeting the glucagon receptor family for diabetes and obesity therapy.
Cho YM; Merchant CE; Kieffer TJ
Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
[TBL] [Abstract][Full Text] [Related]
19. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.
Yang DH; Zhou CH; Liu Q; Wang MW
Acta Pharmacol Sin; 2015 Sep; 36(9):1033-42. PubMed ID: 26279155
[TBL] [Abstract][Full Text] [Related]
20. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.
Unger J
Curr Diab Rep; 2013 Oct; 13(5):663-8. PubMed ID: 23955813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
